Xinshiyan / Newtrials
Clinical trial digital infrastructure: remote monitoring, CTMS and site finance SaaS
About Xinshiyan / Newtrials
Hangzhou Xinshiyan Medical Technology builds SaaS for clinical trials—not ophthalmic hardware. Its public site newtrials.com.cn (and newtrials.cn) markets digital clinical research tools including remote monitoring (CTRM), CTMS, CRA data maps, paper-report digitization, GCP pharmacy/finance workflows, and subject stipend payouts for sponsors, CROs, and hospitals. Founded around 2020 in Hangzhou, Zhejiang, the company has reported multi-million RMB A+ funding (2025) from Zhejiang biopharma industry funds, Sherpa, and Sequoia China Seed, with remote monitoring live in 150+ hospitals and dozens of sponsors including multinational pharma. Prior Dealroom copy incorrectly described ophthalmic microscopes and slit lamps; that identity is wrong for this domain and has been replaced with the clinical-trial SaaS description evidenced by the official product site and 36Kr coverage of Xinshiyan.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Ophthalmology, Surgery, Medical Imaging, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2025 | $2.8M | $69M | Sequoia · Sherpa Venture Partners · Qiantang Industry Development Group | ↗ |
| SERIES A✓Equity / VC | Aug 2023 | $14M | $55M | Eight Roads Ventures · Sherpa Venture Partners · Ariel Investment | ↗ |
Growth signals
Latest recorded traffic for Xinshiyan / Newtrials is 390 monthly website visits, up 25.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xinshiyan / Newtrials in the Hangzhou ecosystem
The Xinshiyan / Newtrials office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Eight Roads Ventures
Sherpa Venture Partners- AIAriel Investment
Sequoia- QGQiantang Industry Development Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xinshiyan / Newtrials on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xinshiyan / Newtrials’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







